| 1999-02 |
Established the De Western Therapeutics Research Institute Ltd. in Nagoya, Aichi Prefecture, for pharmaceutical research and development (capital 5,000 thousand yen). |
| 1999-02 |
Established D.Western Therapeutics Institute, Inc. in Nagoya, Aichi Prefecture for the purpose of conducting pharmaceutical research and development (five million yen capitalization). |
| 2002-09 |
Signed development and implementation agreements with Kowa Co., Ltd. for K-134 (occlusive atherosclerosis) and K-115 (glaucoma/ocular hypertension). |
| 2002-09 |
Signed a development and implementation agreement with Kowa Co., Ltd. for K-115, a drug for treating glaucoma. |
| 2004-11 |
Converted from a limited company to a corporation (capital 10,000 thousand yen). |
| 2004-11 |
Changed from a limited company to a joint-stock corporation (10 million yen capitalization). |
| 2006-12 |
Entered a joint research agreement with Mie University, a national university corporation, and established the "Clinical Drug Discovery Research Course" within the university. |
| 2006-12 |
Entered into an industry-academia-government collaboration agreement with Mie University Faculty of Medicine for joint research, and jointly established Institute of Human Research Promotion and Drug Development at the University. |
| 2009-10 |
Listed shares on the JASDAQ NEO (now Tokyo Stock Exchange Growth Market). |
| 2009-10 |
Listed on JASDAQ Securities Exchange NEO Market (now Tokyo Stock Exchange Growth market). |
| 2013-03 |
Signed a contract granting re-implementation rights for the development, manufacturing, use, and sale of H-1129 (glaucoma/ocular hypertension) in Japan with Wakimoto Pharmaceutical Co., Ltd. |
| 2013-03 |
Signed a contract granting exclusive implementation rights with re-implementation license for the development, manufacturing, use, and sale of H-1129 (glaucoma and ocular hypertension) in Japan by Wakimoto Pharmaceutical Co., Ltd. |
| 2013-10 |
Applied for domestic manufacturing and sales approval of K-115 (glaucoma/ocular hypertension). |
| 2014-09 |
Obtained domestic manufacturing and sales approval for K-115 (product name: Granatac® eye drops 0.4%, generic name: Ripazil hydrochloride hydrate) for glaucoma/ocular hypertension. |
| 2014-12 |
Domestic launch of Granatac® eye drops 0.4% (development code: K-115) for glaucoma/ocular hypertension. |
| 2014-12 |
GLANATEC® ophthalmic solution 0.4% (generic name: Ripasudil hydrochloride hydrate, K-115) for glaucoma launched in Japan. |
| 2015-06 |
Signed an introduction agreement to obtain exclusive implementation rights for an ophthalmic therapeutic agent in Japan (development code: DW-1001). |
| 2015-06 |
Signed an in-licensing agreement to acquire exclusive Japan license for an ophthalmic drug (DW-1001). |
| 2015-11 |
Made Nihon Innovation Pharmaceuticals Inc. a consolidated subsidiary. |
| 2015-11 |
Made Japan Innovative Therapeutics Inc. a consolidated subsidiary. |
| 2017-04 |
Acquired the business related to an ophthalmic surgical adjunct containing BBG250 (development code: DW-1002). |
| 2017-04 |
Received transfer of business related to an ophthalmic surgical adjuvant (DW-1002). |
| 2018-03 |
Commenced Phase I/early Phase II clinical trials in the United States for H-1337 (glaucoma/ocular hypertension), our first in-house developed product. |
| 2018-03 |
Initiatied Phase I/IIa clinical trials of glaucoma treatment (H-1337), DWTI’s first in-house developed product, in the U.S. |
| 2018-08 |
Signed a joint research and license agreement with Glaukos Corporation (USA) for glaucoma treatment products. |
| 2018-08 |
Signed a joint research and licensing agreement with U.S.-based Glaukos Corporation for glaucoma drugs. |
| 2018-09 |
Completed Phase I/early Phase II clinical trials in the United States for H-1337 (glaucoma/ocular hypertension). |
| 2018-09 |
Phase I/IIa clinical trials of H-1337 glaucoma treatment completed in the U.S. |
| 2019-02 |
Obtained import approval for Granatac® eye drops 0.4% (development code: K-115) for glaucoma/ocular hypertension in South Korea. |
| 2019-08 |
Submitted an IND application for a Phase II clinical trial in the United States targeting Fuchs endothelial corneal dystrophy with Ripazil hydrochloride hydrate (development code: K-321). |
| 2019-08 |
Submitted an Investigational New Drug (IND) application for Phase II clinical trials in the U.S. of Ripasudil hydrochloride hydrate as treatment for Fuchs endothelial corneal dystrophy (K-321). |
| 2019-09 |
Discontinued development of H-1129 (glaucoma/ocular hypertension). |
| 2019-12 |
Signed a license agreement with Lotte Pharmaceutical Co., Ltd. granting exclusive implementation rights for DW-1001 in Japan. |
| 2019-12 |
Signed an agreement with Rohto Pharmaceutical Co., Ltd., granting exclusive Japan license for ophthalmic drug DW-1001. |
| 2020-02 |
Start of Phase III clinical trial in Japan for a combination glaucoma treatment (Ripasudil hydrochloride hydrate and Brimonidine tartrate). |
| 2020-02 |
Phase III clinical trials began in Japan for a fixed combination drug for treating glaucoma (Ripasudil hydrochloride hydrate and Brimonidine tartrate [K-232]). |
| 2020-04 |
U.S. launch of DW-1002 (product name: TissueBlue™) (inner limiting membrane staining) and signing of a joint development agreement with Medrex Co., Ltd. for the neuropathic pain drug DW-5LBT. |
| 2020-04 |
Ophthalmic surgical adjuvant DW-1002 (TissueBlue™) launched in the U.S. |
| 2020-08 |
U.S. approval application for DW-5LBT (postherpetic neuralgia). |
| 2020-08 |
Signed a joint development agreement with MEDRx Co., Ltd. for DW-5LBT neuropathic pain treatment. |
| 2020-08 |
Applied for approval of DW-5LBT neuropathic pain treatment in the U.S. |
| 2020-09 |
Addition of target diseases (corneal disorders, retinal diseases) for joint research with Glaukos Corporation in the U.S. and signing of a new license agreement. |
| 2020-09 |
Added new disease types (corneal and retinal disorders) for joint research with U.S.-based Glaukos, and signed a new licensing agreement. |
| 2021-10 |
Canadian launch of DW-1002 (product name: TissueBlue™) (inner limiting membrane staining). |
| 2021-10 |
Ophthalmic surgical adjuvant DW-1002 (TissueBlue™) launched in Canada. |
| 2021-11 |
Domestic manufacturing and sales approval application for K-232 (glaucoma and ocular hypertension). |
| 2021-11 |
Applied for approval of K-232 glaucoma and ocular hypertension in Japan. |
| 2022-03 |
Start of Phase I clinical trial in Japan for DW-1001. |
| 2022-03 |
Phase I clinical trials of DW-1001 began in Japan. |
| 2022-06 |
Signed a joint development agreement with Actuare Co., Ltd. for the regenerative cell product DWR-2206 targeting vesicular keratitis. |
| 2022-06 |
Signed a joint development agreement with ActualEyes Inc. for DWR-2206 regenerative cell therapy for bullous keratopathy. |
| 2022-08 |
Phase III clinical trials of K-321 for Fuchs endothelial corneal dystrophy began in U.S. |
| 2022-08 |
Initiated Phase III clinical trial of K-321 (Fuchs' corneal endothelial dystrophy) in the United States. |
| 2022-12 |
Domestic launch of Gralla® combination eye drops (development code: K-232) (glaucoma and ocular hypertension) and start of Phase II late-stage U.S. clinical trial for H-1337 (glaucoma and ocular hypertension). |
| 2022-12 |
GLA-ALPHA® combination ophthalmic solution (generic name: Ripasudil hydrochloride hydrate, brimonidine tartrate, K-232) for glaucoma and ocular hypertension launched in Japan. |
| 2022-12 |
GLA-ALPHA® combination ophthalmic solution (generic name: Ripasudil hydrochloride hydrate, brimonidine tartrate, K-232) for glaucoma and ocular hypertension launched in Japan. Initiatied Phase IIb clinical trials of glaucoma treatment (H-1337). |
| 2023-03 |
Start of global Phase III clinical trial for K-321 (Fuchs endothelial corneal dystrophy). |
| 2023-03 |
Phase III clinical trials of K-321 for Fuchs endothelial corneal dystrophy began in Global. |
| 2024-03 |
Start of Phase II clinical trial in Japan for DWR-2206 (vesicular keratitis). |
| 2024-03 |
Phase II clinical trials of DWR-2206 for bullous keratopathy began in Japan. |
| 2025-09 |
U.S. approval obtained for DW-5LBT (postherpetic neuralgia). |
| 2025-09 |
Approved of DW-5LBT neuropathic pain treatment in the U.S. |
